Stocks
Altimmune, Inc.ALT
NASDAQHealthcareBiotechnology$3.04
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing peptide-based therapies for obesity and liver diseases. Its lead candidate, pemvidutide, is in Phase 2 trials for weight management and metabolic dysfunction-associated steatohepatitis (MASH). Investors track the stock for its potential in the high-demand GLP-1 agonist market.
52W Range: $2.56-$6.44
Congressional Interest in Altimmune, Inc. (ALT)
No congressional trades have been disclosed for Altimmune, Inc. (ALT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ALT?
No congressional trades found for this stock.